Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty
NCT ID: NCT00772395
Last Updated: 2014-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
78 participants
INTERVENTIONAL
2006-04-30
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
NCT00353080
Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty
NCT01358669
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00402441
Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty
NCT01630941
Denosumab for Treating Periprosthetic Osteolysis.
NCT02299817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risedronate
Risedronate
35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Placebo
Placebo
Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risedronate
35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Placebo
Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary osteoarthritis
* Osteoarthritis secondary to congenital dislocation of the hip
Exclusion Criteria
* Bisphosphonate treatment
* Osteomalacia
* Hypocalcemia
* Previous surgery of the affected hip
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Danderyd Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olof Skoldenberg
Consulatant Orthopaedic Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olof G Sköldenberg, MD
Role: PRINCIPAL_INVESTIGATOR
Department of clinical sciences at Danderyd hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orthopaedic department, Danderyd Hospital
Stockholm, Stockholm County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-745/4
Identifier Type: -
Identifier Source: secondary_id
04-745/4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.